CD8A and acute myeloid leukemia: In vivo studies using RNAi screens in mice indicated bromodomain-containing protein 4 (BRD4) as therapeutic targets in acute myeloid leukaemia (AML), and positive transcription elongation factor (P-TEFb) component Cyclin T1 (Ccnt1) and catalytic partner Cdk9 as regulators of antiviral CD4+ and CD8+ T cell differentiation [87, 90].